Vitiligo
RecruitingStudy of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo
- Disease:Vitiligo
- Substances:Ruxolitinib
Austria- Participants:0–17 years
- Substances:Ruxolitinib
- Sponsor:Incyte Corp.
Rare diseases
Investigational molecules
Locations
1801 Augustine Cut Off, 19803-4404, United States
Incyte Corp. funds research across diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary mediastinal large B-cell lymphoma, and other hematologic malignancies, with additional interest in myelofibrosis, myeloproliferative neoplasms, and myelodysplastic and overlap syndromes. Its portfolio also includes studies in autoimmune hemolytic anemia, immune-mediated thrombocytopenia, and anaemia associated with myelofibrosis.
Research also extends to treatment settings involving relapsed or refractory disease and advanced blood cancers requiring ongoing therapeutic options.
Incyte Corp. runs clinical trials in conditions such as Hidradenitis, Vitiligo, Neurodermatitis, Chronic graft versus host disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Austria
Austria
Austria
Austria
Belgium
France
Belgium
Belgium
Austria
France
Poland
HungaryIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.